QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 enveric-biosciences-granted-us-patent-12065404-today-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-and-methods-used-to-treat-brain-neurological-disorders

https://ppubs.uspto.gov/pubwebapp/external.html?q=(12065404).pn

 aries-science--technology-and-enveric-biosciences-announce-issuance-of-key-us-patent-no-12059393-under-aries-license-for-treatment-of-radiation-dermatitis-and-other-conditions

Enveric and Aries recently announced a Licensing Agreement for patented topical product aimed at treating radiation dermatitis,...

 enveric-biosciences-q2-2024-gaap-eps-023-beats-055-estimate

Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $...

Core News & Articles

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted...

 aries-science--technology-and-enveric-biosciences-announce-licensing-agreement-eligible-to-receive-milestone-payments-of-up-to-61m-on-future-sales-if-all-conditions-met

-SEC Filing

 new-patented-psychedelic-drug-brings-hope-for-brain-disorder-therapies

Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological...

 enveric-biosciences-elevates-eb-003-to-lead-development-candidate-provides-strategic-outlook-and-pipeline-update

EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect...

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 on-may-21-enveric-biosciences-received-letter-from-nasdaq-notifying-co-that-it-regained-compliance-with-minimum-stockholders-equity-requirement

- SEC Filing

 psychedelics-inspired-meds-for-depression-anxiety-addiction-producer-trims-q1-net-loss-yoy-increases-cash-on-hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe ...

 enveric-biosciences-q1-2024-gaap-eps-061-beats-078-estimate

Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $...

 cannabinoids-with-chemotherapy-for-breast-cancer-psychedelics-biotech-inks-61m-license-deal-for-patented-methods

The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as ...

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION